Cargando…

The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs

Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most prevalent and debilitating respiratory diseases worldwide, both associated with high morbidity and mortality rates. As major global health concerns, they impose a substantial burden on patients, healthcare systems, a...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shaughnessy, Megan, Sheils, Orla, Baird, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419288/
https://www.ncbi.nlm.nih.gov/pubmed/37569672
http://dx.doi.org/10.3390/ijms241512296
_version_ 1785088482174042112
author O’Shaughnessy, Megan
Sheils, Orla
Baird, Anne-Marie
author_facet O’Shaughnessy, Megan
Sheils, Orla
Baird, Anne-Marie
author_sort O’Shaughnessy, Megan
collection PubMed
description Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most prevalent and debilitating respiratory diseases worldwide, both associated with high morbidity and mortality rates. As major global health concerns, they impose a substantial burden on patients, healthcare systems, and society at large. Despite their distinct aetiologies, lung cancer and COPD share common risk factors, clinical features, and pathological pathways, which have spurred increasing research interest in their co-occurrence. One area of particular interest is the role of the lung microbiome in the development and progression of these diseases, including the transition from COPD to lung cancer. Exploring novel therapeutic strategies, such as metal-based drugs, offers a potential avenue for targeting the microbiome in these diseases to improve patient outcomes. This review aims to provide an overview of the current understanding of the lung microbiome, with a particular emphasis on COPD and lung cancer, and to discuss the potential of metal-based drugs as a therapeutic strategy for these conditions, specifically concerning targeting the microbiome.
format Online
Article
Text
id pubmed-10419288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104192882023-08-12 The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs O’Shaughnessy, Megan Sheils, Orla Baird, Anne-Marie Int J Mol Sci Review Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most prevalent and debilitating respiratory diseases worldwide, both associated with high morbidity and mortality rates. As major global health concerns, they impose a substantial burden on patients, healthcare systems, and society at large. Despite their distinct aetiologies, lung cancer and COPD share common risk factors, clinical features, and pathological pathways, which have spurred increasing research interest in their co-occurrence. One area of particular interest is the role of the lung microbiome in the development and progression of these diseases, including the transition from COPD to lung cancer. Exploring novel therapeutic strategies, such as metal-based drugs, offers a potential avenue for targeting the microbiome in these diseases to improve patient outcomes. This review aims to provide an overview of the current understanding of the lung microbiome, with a particular emphasis on COPD and lung cancer, and to discuss the potential of metal-based drugs as a therapeutic strategy for these conditions, specifically concerning targeting the microbiome. MDPI 2023-08-01 /pmc/articles/PMC10419288/ /pubmed/37569672 http://dx.doi.org/10.3390/ijms241512296 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
O’Shaughnessy, Megan
Sheils, Orla
Baird, Anne-Marie
The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title_full The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title_fullStr The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title_full_unstemmed The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title_short The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs
title_sort lung microbiome in copd and lung cancer: exploring the potential of metal-based drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419288/
https://www.ncbi.nlm.nih.gov/pubmed/37569672
http://dx.doi.org/10.3390/ijms241512296
work_keys_str_mv AT oshaughnessymegan thelungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs
AT sheilsorla thelungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs
AT bairdannemarie thelungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs
AT oshaughnessymegan lungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs
AT sheilsorla lungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs
AT bairdannemarie lungmicrobiomeincopdandlungcancerexploringthepotentialofmetalbaseddrugs